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Summary
Background and objectives Retinal abnormalities are common in inherited and acquired renal disease. This
study determined the prevalence of retinal abnormalities in chronic kidney disease (CKD) stages 3 to 5.
Design, setting, participants, & measurements One hundred fifty patients with CKD stages 3 to 5 and 150
age- and gender-matched hospital patients with CKD stages 1 to 2 underwent bilateral retinal photography.
These images were reviewed for incidental abnormalities, microvascular (Wong and Mitchell classification)
and diabetic retinopathy (Airlie House criteria), and macular degeneration (Seddon classification).
Results Three (2%) patients with CKD stages 3 to 5 had retinal features characteristic of inherited renal dis-
ease (atrophy in Myopathy, Encephalopathy, Lactic Acidosis, Stroke-like episodes [MELAS] syndrome; and
2 with drusen in dense deposit disease). Fifty-nine (39%) patients had moderate-severe microvascular reti-
nopathy (hemorrhages, exudates, etc.) compared with 19 (13%) with CKD stages 1 to 2. Forty-one (28%)
had moderate-severe diabetic retinopathy (microaneurysms, exudates, etc.) compared with 16 (11%) with
CKD stages 1 to 2. Ten (7%) had severe macular degeneration (geographic atrophy, hemorrhage, exudates,
membranes) compared with one (1%) with CKD stages 1 to 2. Renal failure was an independent risk factor
for microvascular retinopathy, diabetic retinopathy, and macular degeneration. Eleven (7.3%) patients with
renal failure and one (0.7%) with CKD stages 1 to 2 had previously unrecognized vision-threatening retinal
abnormalities that required immediate ophthalmologic attention.
Conclusions Retinal abnormalities are common in CKD stages 3 to 5, and are more severe and more likely
to threaten vision than in hospital patients with CKD stages 1 to 2.
Clin J Am Soc Nephrol 6: 1866–1871, 2011. doi: 10.2215/CJN.10321110
Introduction
Ocular disease, particularly cataracts and subconjunc-
tival calcification, is common in chronic kidney dis-
ease (CKD) stages 3 to 5 (1,2), but retinal abnormali-
ties also occur. These include microvascular and
diabetic retinopathy (2), macular degeneration (3),
hemorrhage, and calcification (4–6).
Retinal hemorrhage occurs in renal failure as a fea-
ture of the moderate-severe forms of microvascular
and diabetic retinopathy and of macular degeneration
(7–9), and is exaggerated by the bleeding tendency in
uremia. Retinal microvascular abnormalities are com-
mon because hypertension, renovascular disease, and
diabetes account for more than half of all patients
with renal failure and also represent “traditional” risk
factors for macro- and microvascular disease. “Non-
traditional” risk factors such as inflammation, calcifi-
cation, and endothelial dysfunction may contribute to
the increased vascular risk, too (10–12). Diabetes is
the single most common cause of CKD worldwide,
and many patients with diabetes-associated renal fail-
ure also have retinopathy. In addition, recent popu-
lation-based studies suggest that macular degenera-
tion is increased in renal impairment (3). Risk factors
common to renal failure and macular degeneration
include increasing age, smoking, and possibly hyper-
tension (13,14).
Many renal diseases also have characteristic retinal
features. This is particularly true of inherited renal
disease because the inner retina and glomerular fil-
tration barrier share developmental pathways (15)
and structural features (16), including ciliated epithe-
lial cells (17), basement membranes comprising
345 collagen IV, and the extensive capillary beds
seen in the choriocapillaris and glomerulus (18). Ret-
inal abnormalities in inherited renal disease include
drusen (Alport syndrome, dense deposit disease),
coloboma (reflux nephropathy), retinitis pigmentosa
(nephronophthisis; Myopathy, Encephalopathy, Lac-
tic Acidosis, Stroke-like episodes [MELAS] syn-
drome), crystal deposits (oxalosis, cystinosis), and
vascular anomalies (Hereditary Angiopathy, Ne-
phropathy, and muscle Cramps syndrome; Fabry dis-
ease) (19,20). Retinal effects in acquired renal disease
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include vasculitis and infarcts in systemic lupus erythem-
atosus, Wegener granulomatosis and microscopic polyan-
gitis (21,22), and possibly central serous retinopathy in
Goodpasture syndrome, in which antibodies bind to the
internal limiting and Bruch membranes (23). These fea-
tures are all helpful diagnostically, but it is unclear how
often they occur in the typical hospital patient.
We describe here a cross-sectional observational study of
patients with CKD stages 3 to 5 from a hospital ward or
ambulatory clinic that demonstrated the prevalence of ret-
inal abnormalities, their severity, and their relationship
with renal failure.
Study Population and Methods
Study Population
This was a cross-sectional observational study of 150
hospital patients with CKD stages 3 to 5 (estimated GFR
[eGFR] 60 ml/min per 1.73 m2 for at least 3 months) and
150 age- and gender-matched patients with CKD stages 1
to 2 (eGFR 60 ml/min per 1.73 m2) who were recruited
from a renal ambulatory clinic at one teaching hospital,
and a renal clinic and general medical ward at another. The
participation rate was 80% of individuals approached.
The clinic patients were recruited over an 18-month period,
and the ward patients over 3 months. eGFR was calculated
using serum creatinine estimated with a Beckman Coulter
instrument and the Modification of Diet in Renal Disease
175 equation. The laboratory did not stipulate values for
eGFR60 or90 ml/min per 1.73 m2 for the first year and
the final 6 months, respectively, of the study, so all patients
with these levels were classified as CKD stages 1 to 2.
Proteinuria was not measured. Patients on dialysis were
included in the study because they represented a large
proportion of those with CKD stage 5. Patients with a renal
transplant were excluded because of a possible effect on
vascular disease.
Controls were age- and gender- matched patients with
CKD stages 1 to 2 from the clinics and ward who were
recruited in parallel with those with CKD stages 3 to 5.
Hospital patients were chosen as controls because they were
well characterized and had similar comorbidities (hyperten-
sion, diabetes) as the patients with CKD stages 3 to 5.
The study was approved by the Human Research Ethics
Committee of Northern Health and Austin Health in ac-
cordance with the principles of the Declaration of Helsinki,
and all participants provided signed, informed consent.
Study Assessments
Participants underwent a structured medical interview
to identify the underlying renal disease and previously
diagnosed hypertension (140/90 mmHg), diabetes (ran-
dom serum glucose 11.0 mmol/L), dyslipidemia (serum
cholesterol 5.0 mmol/L, HDL 2.0 mmol/L, or statin
use), smoking history, and ophthalmologic disease. Labo-
ratory test results (hemoglobin, lipids, hemoglobin A1c)
were obtained from the patients’ medical records.
Retinal Imaging and Grading
Participants underwent bilateral retinal photography af-
ter dark adaptation or dilation with 0.5% tropicamide. At
least one image was centered on the macula and another
on the optic disc using a KOWA 7 (Kowa Optimed, Inc.,
Torrance, CA) or Canon CR5-45 (Canon, Tokyo, Japan)
nonmydriatic retinal camera.
Photographs were coded, reviewed for incidental abnor-
malities and hemorrhage, and graded for microvascular
retinopathy (7), diabetic retinopathy (8), and macular de-
generation by an ophthalmologist and trained observer
independently (9). “Red-free” images were examined in all
patients to identify hemorrhage and other features. The
grade of the more severely affected eye was used in any
individual.
Statistical Analyses
Fisher two-tailed test or chi-squared test with Yates cor-
rection was used to compare dichotomous variables, and a
t test was used for continuous variables. Multivariate lo-
gistic regression was performed to determine whether
variables had an independent effect on outcome. A result
was significant if the odds ratio (OR) was greater or less
than 1, the 95% confidence interval (CI) did not include
1.00, and the P value was less than 0.05. Statistical analyses
were performed using STATA version 10 software (Stata
Corporation, College Station, TX).
Results
Clinical Features of Patients with CKD Stages 3 to 5 or
CKD Stages 1 to 2
Both groups comprised 96 men (64%) and 54 women
(36%) with a median age of 62 years (range 20 to 85 years).
In the patients with CKD stages 3 to 5, renal failure was
due to diabetes (54, 36%); glomerulonephritis (38, 25%);
hypertension/renovascular disease (26, 17%); reflux or
other structural malformations (8, 5%); polycystic kidney
disease (7, 5%); cancer, trauma, and nephrotoxic agents (9,
6%); or unknown causes (8, 5%). These patients had CKD
stage 3 (n  48, 32%), stage 4 (n  40, 27%) or stage 5 (n 
62, 42%), and 49 patients (32%) were dialysis-dependent.
Their overall median eGFR was 19 ml/min per 1.73 m2
(range 3 to 59 ml/min per 1.73 m2) compared with 90
ml/min per 1.73 m2 (range 60 to 90 ml/min per 1.73 m2) in
patients with CKD stages 1 to 2 (P  0.001).
Patients with CKD stages 3 to 5 had more hypertension
than those with CKD stages 1 to 2 (123, 82% and 68, 45%,
respectively; OR 5.49, CI 3.25 to 9.30, P  0.001), more
diabetes (64, 43% and 35, 23%, respectively; OR 2.45, CI
1.49 to 4.02, P  0.001) and more dyslipidemia (106 of 143,
74% and 66 of 143, 46%, respectively; OR 3.34, CI 2.03 to
5.50, P 0.001). They were less likely to have smoked than
patients with CKD 1 and 2 (78, 52% and 100, 67%, respec-
tively; OR 0.54, CI 0.34 to 0.86, P  0.01), and they had a
lower mean hemoglobin level (119.9  20 g/L compared
with 135.3  18 g/L, P  0.0001).
Incidental Retinal Abnormalities
Three (16.7%) of the 18 patients with CKD stages 3 to 5
and known inherited renal disease had associated retinal
abnormalities. These were two patients with macular
drusen due to dense deposit disease, and one with MELAS
syndrome and retinal atrophy (Figure 1). All three had
impaired vision. In all cases, the renal diagnosis was
known but the retinal complications were not recognized
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previously. No coloboma or crystals, no tortuous vessels
typical of Fabry disease or Hereditary Angiopathy, Ne-
phropathy, and muscle Cramps syndrome, and no infarcts
or calcification were seen in any of the other patients. There
were no significant retinal findings in the patients with
CKD stages 1 to 2 apart from those described below.
Retinal Abnormalities
Retinal hemorrhage, microvascular and diabetic retinop-
athy, and macular degeneration were all more common in
patients with CKD stages 3 to 5 than in those with CKD
stages 1 to 2 (Table 1, Figure 1). Retinal images were
gradeable for microvascular retinopathy in all patients, but
in patients with CKD stages 3 to 5 they were ungradeable
for diabetic changes in one patient and for macular degen-
eration in 10 patients. Images were ungradeable in two
patients with CKD stages 1 to 2 for macular degeneration.
Poor images were generally due to coincidental cataract.
Hemorrhage
Retinal hemorrhage was present in 59 (39%) patients
with CKD stages 3 to 5, microvascular retinopathy in 101
(67%) patients, diabetic retinopathy in 41 (28%) patients,
Figure 1. | Retinal appearances in patients with chronic kidney
disease stages 3 to 5: (a) thrombosed vessel and retinal atrophy
secondary to severe hypertension in focal segmental glomeruloscle-
rosis, (b) multiple hemorrhages from retinal vein thrombosis, (c)
undiagnosed diabetic retinopathy, (d) fibrous change in diabetic
retinopathy with hemorrhage and exudates, (e) central drusen in
macular degeneration, (f) severe geographic atrophy in macular
degeneration, (g) macular drusen in a young patient with dense
deposit disease, and (h) retinal atrophy in patient with focal seg-
mental glomerulosclerosis and Myopathy, Encephalopathy, Lactic
Acidosis, Stroke-like episodes syndrome.
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and macular degeneration (drusen within 2 disc diameters
of the macula) in 62 (44%) patients.
Retinal hemorrhage was increased in patients with CKD
stages 3 to 5 (59, 39%) compared with CKD stages 1 to 2
(19, 13%) (OR 4.47, CI 2.5 to 8.0, P  0.0001). Hemorrhage
varied from microaneurysms to multiple, large bleeds in-
cluding retinal vein occlusion in one patient (Figure 1).
Most bleeds were small, transient, and of no visual conse-
quence.
The odds of hemorrhage in CKD stages 3 to 5 were
increased with hypertension (OR 4.34, CI 1.97 to 9.55, P 
0.0001), diabetes (OR 4.63, CI 1.82 to 11.75, P  0.01), and
low hemoglobin level (mean difference 10.70, CI 15.91
to 05.49, P  0.001) but not with aspirin use (P  0.63) on
univariate analysis. On multivariate analysis, hemorrhage
was increased with renal impairment (OR 4.22, CI 2.08 to
8.56, P  0.001), diabetes (OR 4.29, CI 2.31 to 7.99,
P 0.001), and smoking (OR 2.35, CI 1.20 to 4.59, P 0.01)
after adjusting for age, gender, hypertension, dyslipide-
mia, and anemia.
Microvascular Retinopathy
Microvascular retinopathy was more common in CKD
stages 3 to 5 than CKD stages 1 to 2. One hundred one
(67%) patients with CKD stages 3 to 5 had a mild or
moderate microvascular retinopathy (focal or generalized
arteriolar narrowing, arteriovenous nicking, hemorrhage,
exudates, etc.; Table 1) compared with 66 (44%) patients
with CKD stages 1 to 2 (OR 2.62, CI 1.64 to 4.20, P  001).
Fifty-nine (39%) patients with CKD stages 3 to 5 had mod-
erate-severe microvascular changes (hemorrhage, exu-
dates) compared with 19 (13%) patients with CKD stages 1
to 2 (OR 4.47, CI 2.50 to 8.00, P  0.0001). Moderate-severe
microvascular retinopathy became more common as the
hypertension worsened as assessed by the number of an-
tihypertensive agents needed for treatment. Thus, 10 of the
40 patients (25%) with CKD stages 3 to 5 who were using
two antihypertensives had a moderate-severe retinopathy
compared with 16 of the 31 (51.6%) who were treated with
at least four agents (P 0.027). Moderate-severe microvas-
cular retinopathy was just as common in patients with
CKD stage 5 on dialysis as not (22 of 48, 46% and 7 of 18,
39%, P  0.78). None of the patients had severe microvas-
cular retinopathy with papilledema. Moderate microvas-
cular changes became more common as renal function
deteriorated (P  0.001).
Multivariate analysis demonstrated that reduced eGFR
(OR 2.85, CI 1.63 to 5.00, P  0.001) as well as diabetes (OR
1.83, CI 1.06 to 3.16, P  0.03), and a smoking history (OR
1.71, CI 1.00 to 2.93, P  0.05) were independent risk
factors for microvascular retinopathy after adjusting for
age, gender, hypertension, and dyslipidemia.
Diabetic Retinopathy
Sixty-four (47%) patients with CKD stages 3 to 5 and 35
(23%) patients with CKD stages 1 to 2 had diabetes. Dia-
betic retinopathy was more common in CKD stages 3 to 5
than CKD stages 1 to 2. Forty-one (41 of 149, 28%) patients
with CKD stages 3 to 5 had a moderate-severe diabetic
retinopathy (grades 37 to 65, with at least microaneurysms
and exudates) compared with 16 (11%) patients with CKD
stages 1 to 2 (OR 3.18, CI 1.69 to 5.98, P  0.001). In
addition, diabetic retinopathy became more common as
renal function deteriorated in CKD stages 3 to 5 (P 
0.001). Hemoglobin A1c was not different in patients with
diabetic retinopathy with CKD stages 3 to 5 compared with
CKD stages 1 to 2 (7.9 1.81 and 8.5 2.34%, respectively,
P  0.30).
Proliferative changes (grades 60 to 65, with new vessels,
photocoagulation scars, or fibrous proliferation) were also
more common in CKD stages 3 to 5 than CKD stages 1 to
2 (18 of 149, 12% compared with 2 of 150, 1%, OR 10.17, CI
2.32 to 44.65, P  0.001) and similarly became more com-
mon as renal function deteriorated (P  0.001). Two pa-
tients without known diabetes had a proliferative diabetic
retinopathy.
Multivariate analysis confirmed that diabetes (OR 5.94,
CI 3.04 to 11.62, P  0.001) and reduced eGFR (OR 2.18, CI
1.02 to 4.66, P  0.04) were independent risk factors for
diabetic retinopathy after adjusting for age, gender, hyper-
tension, dyslipidemia, and smoking history.
Macular Degeneration
Macular degeneration (large, soft perimacular drusen,
geographic atrophy, hypo- and hyperpigmentation) was
increased in patients with CKD stages 3 to 5 compared
with patients with CKD stages 1 to 2. Sixty-two (62 of 140,
44%) patients with CKD stages 3 to 5 had these changes
compared with 43 (43 of 148, 29%) patients with CKD
stages 1 to 2 (OR 1.94, CI 1.19 to 3.16, P  0.010). Severe
changes (grades 4 to 5) were increased in patients with
CKD stages 3 to 5 (OR 11.31, CI 1.43 to 89.54, P  0.005)
and became more common as renal function deteriorated
(P  0.02). Four patients with CKD stages 3 to 5 were
technically blind from undiagnosed macular degeneration
and were referred for urgent ophthalmologic review.
Multivariate analysis confirmed that age (OR 1.04, CI
1.02 to 1.07, P  0.0001) and CKD stages 3 to 5 (OR 1.79, CI
1.00 to 3.20, P  0.05) were independent determinants of
macular degeneration after adjusting for gender, hyperten-
sion, diabetes, dyslipidemia, and smoking history.
Patients Requiring Urgent Ophthalmologic Review
One hundred nineteen (79%) patients with CKD stages 3
to 5 were found in this study to have pathologic retinal
abnormalities. These included 82 (55%) patients with
changes related to diabetes, macular degeneration, or other
significant disease (MELAS syndrome, retinal vein throm-
bosis, etc.). Sixty-seven (45%) patients with normal renal
function had pathologic abnormalities: 16 (11%) with dia-
betic retinopathy and 1 with late macular degeneration.
Eleven patients with CKD stages 3 to 5 (7%) with a
previously undetected retinal abnormality were referred
for urgent ophthalmologic review. This was for the retinal
complications of dense deposit disease (n  2) or MELAS
syndrome (n  1), proliferative diabetic retinopathy (n 
3), macular degeneration (n 4), or retinal vein thrombosis
(n  1). One person with CKD stage 1 to 2 was referred for
ophthalmologic management of a diabetic proliferative ret-
inopathy. Thus, patients with CKD stages 3 to 5 were more
likely to have retinal abnormalities that required urgent
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ophthalmologic review than other hospital patients (2
with Yates correction  7.03, P  0.001).
Discussion
Hospital patients from the wards and clinics with CKD
stages 3 to 5 were more likely to have retinal hemorrhage,
microvascular and diabetic retinopathy, and macular degen-
eration than patients with CKD stages 1 to 2. In general,
retinal abnormalities were also more severe in patients with
CKD stages 3 to 5 and worsened as renal function deterio-
rated. Retinal changes that threatened vision were also more
common in CKD stages 3 to 5 than in other hospital patients,
and resources should focus on this patient group.
Retinal Screening for the Diagnosis of Renal Disease
The demonstration of associated retinal features potentially
aids in the diagnosis of some forms of renal disease. This is
particularly true of inherited renal disease including Alport
syndrome. Eighteen patients with CKD stages 3 to 5 in this
study were known to have inherited renal disease, and three
were demonstrated to have previously unrecognized retinal
abnormalities (i.e., retinal atrophy in MELAS syndrome and
macular drusen in dense deposit disease). Vision was already
impaired at the time of examination and was likely to con-
tinue to deteriorate in all three patients. Although there is
currently no treatment for these diseases, regular ophthalmo-
logic monitoring may prevent complications such as retinal
hemorrhage or detachment and help preserve vision.
This study did not identify any previously undiagnosed
renal disease on the basis of the retinal features, possibly
because the renal diagnosis was likely to be known by
adulthood, many abnormalities in acquired disease resolve
after presentation, and some diagnostic abnormalities are
demonstrated only with peripheral retinal photographs or
special techniques such as optical coherence tomography.
Retinal Hemorrhage
Retinal hemorrhage was found in nearly 40% of patients
with CKD stages 3 to 5. This was because hemorrhage is
present in hypertension, diabetes, and macular degeneration,
all of which were increased in patients in CKD stages 3 to 5,
in addition to the tendency for uremic bleeding. Hemorrhage
typically did not affect vision, andmany small bleedswere only
evident using red-free images. Hemorrhage alone did not war-
rant ophthalmologic review except where it reflected moderate
or severe forms of diabetic retinopathy ormacular degeneration.
Retinal hemorrhage in patients with CKD stages 1 to 2 probably
occurred because of associated patient comorbidities.
Microvascular Retinopathy
Microvascular retinopathy occurred in two thirds of the
patients with renal failure, and nearly 40% had moderate-
severe changes. The retinal vein occlusion may have oc-
curred as a complication of hypertension (24). Although
many retinal microvascular features are also present in
hypertension, multivariate analysis of patients in this
study demonstrated an effect independent of hyperten-
sion. This may involve the nontraditional pathways for
vascular risk such as inflammation, disturbed calcium ho-
meostasis, and endothelial dysfunction (10–12). We did
not assess hypertension on a single BP reading but on a
previous expert diagnosis. The relationship demonstrated
here between hypertension and microvascular retinopathy
presumably occurred because the hypertension was rela-
tively poorly controlled.
In other high-risk populations, retinal microvascular ab-
normalities predict an increased likelihood of coronary
heart disease, stroke, and death (25–27) and correlate with
declining renal function (28,29).
Diabetic Retinopathy
Diabetic retinopathy was also more common and more
severe in renal failure. Patients with undiagnosed diabetes
and unrecognized proliferative retinopathy were identified
among the patients with CKD stages 3 to 5. The increased
severity of retinal complications in diabetic renal failure em-
phasizes the need for regular monitoring because the retinop-
athy is asymptomatic, may progress rapidly if untreated, and
visual loss can be prevented or limited with treatment. The
presence of a diabetic retinopathy is also a marker of in-
creased risk of cardiac disease and death (30).
Macular Degeneration
Macular degeneration was also more common and more
severe in patients with CKD stages 3 to 5. The definition of
macular degeneration included drusen within 2 disc diame-
ters of the foveola. These must be distinguished from the
smaller, more widespread drusen sometimes seen in glomer-
ulonephritis (31) and other systemic inflammatory conditions.
Most patients with macular degeneration including
those with impaired vision were unaware of their diagno-
sis. We identified four patients with reduced eGFR and
previously unrecognized late-stage macular degeneration
that should have been monitored to prevent complications.
This study found age and renal failure, but not hyper-
tension, were major determinants of macular degeneration,
although it remains difficult to dissect out the independent
effects of renal failure and hypertension. Age is a consis-
tent risk factor in other series and hypertension in some,
possibly through reducing the ability of the choroidal cir-
culation to clear drusen (32,33). The maculopathy in renal
failure is probably mainly inflammatory in nature (34).
Again, patients with reduced eGFR should be screened for
macular degeneration because of its consequences for vi-
sion and the possibility of preventing complications.
Screening to Preserve Vision
In general, microvascular retinopathy is considered non-
vision-threatening, but this is not so for diabetic retinopa-
thy and macular degeneration. Patients with diabetes
should undergo retinal screening every 2 years and more
often if abnormalities are present. Patients with macular
degeneration grades 4 and 5 require an ophthalmologic
assessment. Interventions preserve vision in diabetes, and
monitoring may prevent complications in macular degen-
eration and other retinal diseases.
In this study, 11 patients with reduced eGFR required
urgent ophthalmologic review using current international
guidelines. Some had visual loss that could be halted, if not
reversed, by interventions such as laser therapy. For oth-
ers, review and treatment might prevent further complica-
tions. None of the four patients with diabetic retinopathy
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had attended for their routine ophthalmologic screening
despite hospital visits for dialysis and renal review.
In conclusion, moderate-severe microvascular retinopa-
thy, proliferative diabetic retinopathy, and late-stage mac-
ular degeneration are common, severe, and threaten vision
in hospital patients with stages CKD stages 3 to 5. These
changes occur more often and are more severe than in
patients with CKD stages 1 to 2. Early recognition, moni-
toring, and intervention will result in a better visual out-
come for these patients.
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